lhs_bans-01.jpg
 
 
cardiol (logo)-01.png

Cardiol Therapeutics is a biotechnology company specializing in the research and commercial development of novel drug therapies utilizing proprietary drug-delivery systems.

Cardiol brings together a wealth of research and development experience, advanced manufacturing capabilities, and a Management team, Board of Directors, and Scientific Advisory Board comprising business and thought leaders with extensive industry experience and expertise in commercializing proprietary drugs.

We are leveraging our expertise in pharmaceutical cannabinoids to develop proprietary formulations for commercial development in three important medical markets, namely: commercializing a line of pharmaceutically-manufactured pure cannabidiol products in the growing market for medical cannabinoids, developing nanotechnologies designed to deliver cannabinoids and other anti-inflammatory drugs for the treatment of heart failure; and pursuing an immunotherapeutics program commencing with an innovative cancer immunotherapeutic in combination with cannabinoids for Glioblastoma Multiforme, a Fast Track eligible orphan indication.